{"id":"vehicle-ophthalmic-solution","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does not contain any active ingredients and is used to relieve dryness and irritation in the eyes. This solution is often used after eye surgery or to help with conditions such as dry eye syndrome.","oneSentence":"Vehicle ophthalmic solution is a clear liquid used to lubricate the eyes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:31.807Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relief of dryness and irritation in the eyes"}]},"trialDetails":[{"nctId":"NCT04499248","phase":"PHASE1, PHASE2","title":"AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-11-16","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":96},{"nctId":"NCT07224529","phase":"PHASE4","title":"Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Meibomian Gland Dysfunction (MGD)","enrollment":48},{"nctId":"NCT06542497","phase":"PHASE3","title":"Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-08-15","conditions":"Presbyopia","enrollment":569},{"nctId":"NCT05646719","phase":"PHASE3","title":"Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2022-12-22","conditions":"Presbyopia","enrollment":333},{"nctId":"NCT06349759","phase":"PHASE3","title":"Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-04-01","conditions":"Mesopic Vision, Night Vision Loss","enrollment":200},{"nctId":"NCT05728944","phase":"PHASE3","title":"Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2023-03-06","conditions":"Presbyopia, Near Vision, Refractive Error","enrollment":229},{"nctId":"NCT06244316","phase":"PHASE2","title":"A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2024-01-22","conditions":"Dry Eye Disease","enrollment":317},{"nctId":"NCT07264517","phase":"PHASE2","title":"Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).","status":"RECRUITING","sponsor":"Instituto Grifols, S.A.","startDate":"2025-11-03","conditions":"Dry Eye Disease","enrollment":100},{"nctId":"NCT07395232","phase":"PHASE3","title":"An Efficacy and Safety Study of DFL24498 in the Treatment of AKC","status":"RECRUITING","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2025-12-01","conditions":"Atopic Keratoconjunctivitis","enrollment":138},{"nctId":"NCT07370584","phase":"PHASE1","title":"A Safety Study of IVMED-85 Ophthalmic Solution in Healthy Adults","status":"RECRUITING","sponsor":"iVeena Delivery Systems, Inc.","startDate":"2026-02-04","conditions":"Safety Study","enrollment":36},{"nctId":"NCT06919081","phase":"PHASE2","title":"Efficacy of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2025-08-01","conditions":"Persistent Corneal Epithelial Defect, Corneal Epithelial Disorders","enrollment":24},{"nctId":"NCT06978244","phase":"PHASE1","title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-07-29","conditions":"Ocular Pain","enrollment":24},{"nctId":"NCT06538662","phase":"PHASE3","title":"An Investigation of FID 123320 for the Reduction of Ocular Redness in Pediatric and Adult Populations","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-10-07","conditions":"Ocular Redness, Eye Irritation","enrollment":283},{"nctId":"NCT05411367","phase":"PHASE3","title":"A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye","status":"COMPLETED","sponsor":"Seikagaku Corporation","startDate":"2022-07-28","conditions":"Dry Eye Disease","enrollment":232},{"nctId":"NCT03918915","phase":"PHASE3","title":"The Safety and Efficacy of SYD-101 in Children With Myopia","status":"COMPLETED","sponsor":"Sydnexis, Inc.","startDate":"2019-04-24","conditions":"Nearsightedness, Near Sightedness, Near-sightedness","enrollment":852},{"nctId":"NCT05066997","phase":"PHASE2, PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2021-10-19","conditions":"Diabetic Macular Edema","enrollment":552},{"nctId":"NCT06172257","phase":"PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2024-03-15","conditions":"Diabetic Macular Edema","enrollment":401},{"nctId":"NCT05555589","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2","status":"RECRUITING","sponsor":"ReGenTree, LLC","startDate":"2023-04-11","conditions":"Neurotrophic Keratopathy","enrollment":70},{"nctId":"NCT06493604","phase":"PHASE3","title":"A Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2024-06-24","conditions":"Dry Eye Disease","enrollment":116},{"nctId":"NCT07245017","phase":"EARLY_PHASE1","title":"JN002 for the Treatment of Dry Eye Disease","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-11-24","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT04735393","phase":"PHASE3","title":"A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2021-01-26","conditions":"Dry Eye Disease","enrollment":757},{"nctId":"NCT05136170","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-01-27","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT07220408","phase":"PHASE2","title":"Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis","status":"RECRUITING","sponsor":"Telios Pharma, Inc.","startDate":"2025-10-23","conditions":"Allergic Conjunctivitis","enrollment":60},{"nctId":"NCT06441643","phase":"PHASE2","title":"Next Generation Rocklatan","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-09-04","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":426},{"nctId":"NCT07234318","phase":"","title":"Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears","status":"NOT_YET_RECRUITING","sponsor":"Laboratoires Thea","startDate":"2025-12-15","conditions":"Dry Eye Disease (DED)","enrollment":25},{"nctId":"NCT06444529","phase":"PHASE3","title":"A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-08-21","conditions":"Ocular Redness","enrollment":159},{"nctId":"NCT05727878","phase":"PHASE2","title":"Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED","status":"TERMINATED","sponsor":"Combangio, Inc","startDate":"2023-02-07","conditions":"Persistent Corneal Epithelial Defect","enrollment":103},{"nctId":"NCT04638660","phase":"PHASE3","title":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2020-12-30","conditions":"Dim Light Vision Disturbances","enrollment":144},{"nctId":"NCT05486728","phase":"PHASE2","title":"Phase II Study of SHJ002 Sterile Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease","status":"COMPLETED","sponsor":"Dreamhawk Vision Biotech, Inc.","startDate":"2023-02-08","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT04675151","phase":"PHASE2","title":"Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2021-02-15","conditions":"Presbyopia","enrollment":150},{"nctId":"NCT05454956","phase":"PHASE2","title":"Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD","status":"COMPLETED","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2022-08-03","conditions":"Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation","enrollment":39},{"nctId":"NCT07140783","phase":"PHASE3","title":"OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity","status":"RECRUITING","sponsor":"Ocuphire Pharma, Inc.","startDate":"2025-09-02","conditions":"Vision Loss Night, Vision Disorders","enrollment":200},{"nctId":"NCT06424444","phase":"PHASE3","title":"A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2024-04-29","conditions":"Dry Eye Disease","enrollment":421},{"nctId":"NCT06520202","phase":"PHASE1, PHASE2","title":"RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE","status":"TERMINATED","sponsor":"Lubris Bio Pty Ltd","startDate":"2024-11-05","conditions":"Sjogren's Syndrome With Dry Eye","enrollment":8},{"nctId":"NCT05456425","phase":"PHASE3","title":"A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cloudbreak Therapeutics, LLC","startDate":"2022-06-30","conditions":"Pterygium","enrollment":660},{"nctId":"NCT07109609","phase":"PHASE2","title":"Topical Menthol For Tear Secretion","status":"ENROLLING_BY_INVITATION","sponsor":"Reinhold Vieth","startDate":"2025-08-17","conditions":"Healthy, Dry Eyes","enrollment":30},{"nctId":"NCT04130802","phase":"PHASE2","title":"OCS-01 in Treating Inflammation and Pain in Post-cataract Patients","status":"COMPLETED","sponsor":"Oculis","startDate":"2019-09-27","conditions":"Inflammation Corneal, Pain, Postoperative","enrollment":153},{"nctId":"NCT07164092","phase":"PHASE2, PHASE3","title":"Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-09","conditions":"Myopia","enrollment":45},{"nctId":"NCT05636228","phase":"PHASE2","title":"Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis","status":"COMPLETED","sponsor":"Invirsa, Inc.","startDate":"2023-06-09","conditions":"Acute Infectious Keratoconjunctivitis","enrollment":93},{"nctId":"NCT06381986","phase":"PHASE2","title":"Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients","status":"COMPLETED","sponsor":"Sunhawk Vision Biotech, Inc.","startDate":"2024-06-28","conditions":"Corneal Erosion","enrollment":116},{"nctId":"NCT05493111","phase":"PHASE3","title":"A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2022-11-01","conditions":"Dry Eye Disease","enrollment":275},{"nctId":"NCT07120308","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects Caused by Neurotrophic Keratitis","status":"COMPLETED","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2021-09-15","conditions":"Corneal Epithelial Defect","enrollment":28},{"nctId":"NCT05135286","phase":"PHASE3","title":"Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia","status":"COMPLETED","sponsor":"Visus Therapeutics","startDate":"2022-03-15","conditions":"Presbyopia","enrollment":629},{"nctId":"NCT06209320","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2022-03-15","conditions":"Myopia","enrollment":777},{"nctId":"NCT05360966","phase":"PHASE3","title":"Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2022-07-18","conditions":"Dry Eye Disease","enrollment":467},{"nctId":"NCT05285644","phase":"PHASE3","title":"Study Evaluating the Safety and Efficacy of AR-15512","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2022-05-09","conditions":"Dry Eye Disease","enrollment":465},{"nctId":"NCT07068958","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"ORA, Inc.","startDate":"2025-08-01","conditions":"Dry Eye Disease (DED)","enrollment":200},{"nctId":"NCT05147233","phase":"PHASE3","title":"A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery","status":"COMPLETED","sponsor":"Oculis","startDate":"2022-06-24","conditions":"Inflammation Eye Pain, Postoperative Cataract","enrollment":241},{"nctId":"NCT06352541","phase":"PHASE1","title":"Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-09-30","conditions":"Healthy","enrollment":28},{"nctId":"NCT05815758","phase":"PHASE3","title":"Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2023-04-20","conditions":"Allergic Conjunctivitis","enrollment":512},{"nctId":"NCT05896670","phase":"PHASE2","title":"Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Oculis","startDate":"2023-11-29","conditions":"Dry Eye Disease","enrollment":122},{"nctId":"NCT06182358","phase":"PHASE4","title":"Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers","status":"COMPLETED","sponsor":"Tarsus Pharmaceuticals, Inc.","startDate":"2023-12-27","conditions":"Demodex Blepharitis","enrollment":145},{"nctId":"NCT06370039","phase":"PHASE2","title":"Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease","status":"COMPLETED","sponsor":"Invirsa, Inc.","startDate":"2024-03-27","conditions":"Dry Eye Disease","enrollment":109},{"nctId":"NCT05591755","phase":"PHASE3","title":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination in Adults With Seasonal Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-11-18","conditions":"Seasonal Allergic Conjunctivitis","enrollment":229},{"nctId":"NCT06164743","phase":"PHASE2","title":"Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery","status":"COMPLETED","sponsor":"VivaVision Biotech, Inc","startDate":"2024-01-11","conditions":"Inflammation","enrollment":91},{"nctId":"NCT06389214","phase":"PHASE3","title":"A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2024-04-09","conditions":"Dry Eye Disease","enrollment":132},{"nctId":"NCT04734210","phase":"PHASE2","title":"Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-07","conditions":"Dry Eye Disease","enrollment":139},{"nctId":"NCT02128113","phase":"PHASE2","title":"RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD","status":"COMPLETED","sponsor":"Biogen","startDate":"2014-05-31","conditions":"Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation","enrollment":307},{"nctId":"NCT04030962","phase":"PHASE1, PHASE2","title":"A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-03-04","conditions":"Dry Eye Disease, Dry Eye Syndrome","enrollment":292},{"nctId":"NCT04276558","phase":"PHASE2","title":"REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients","status":"COMPLETED","sponsor":"RECORDATI GROUP","startDate":"2020-10-13","conditions":"Neurotrophic Keratitis","enrollment":108},{"nctId":"NCT04734197","phase":"PHASE2","title":"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-11","conditions":"Dry Eye Disease","enrollment":349},{"nctId":"NCT04565756","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Tolerability of EXN407","status":"COMPLETED","sponsor":"Exonate Limited","startDate":"2020-11-05","conditions":"Diabetic Macular Edema","enrollment":48},{"nctId":"NCT05992922","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants","status":"TERMINATED","sponsor":"Iacta Pharmaceuticals","startDate":"2023-10-17","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT03660878","phase":"PHASE1, PHASE2","title":"A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2018-09-08","conditions":"Allergic Conjunctivitis","enrollment":52},{"nctId":"NCT06906198","phase":"PHASE1","title":"Pharmacokinetics of VVN461 Ophthalmic Solution","status":"COMPLETED","sponsor":"VivaVision Biotech, Inc","startDate":"2023-03-01","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT04674358","phase":"PHASE2, PHASE3","title":"The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2020-11-21","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":329},{"nctId":"NCT05062330","phase":"PHASE3","title":"The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2021-08-28","conditions":"Dry Eye","enrollment":361},{"nctId":"NCT03916042","phase":"PHASE2","title":"A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2019-04-23","conditions":"Dry Eye","enrollment":206},{"nctId":"NCT06045299","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia","status":"COMPLETED","sponsor":"Corxel Pharmaceuticals","startDate":"2023-09-27","conditions":"Presbyopia, Near Vision, Miosis","enrollment":300},{"nctId":"NCT03709121","phase":"PHASE1, PHASE2","title":"A Methodology Development Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis Using the Environmental Exposure Chamber","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2018-10-02","conditions":"Conjunctivitis, Allergic","enrollment":70},{"nctId":"NCT04971031","phase":"PHASE2","title":"A Clinical Trial to Assess Subjects With Dry Eye Disease.","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2021-06-15","conditions":"Dry Eye","enrollment":158},{"nctId":"NCT05579730","phase":"PHASE3","title":"Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2022-10-12","conditions":"Allergic Conjunctivitis","enrollment":188},{"nctId":"NCT03494504","phase":"PHASE3","title":"ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2018-03-30","conditions":"Allergic Conjunctivitis","enrollment":318},{"nctId":"NCT03131154","phase":"PHASE3","title":"SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2017-04-26","conditions":"Non-infectious Anterior Uveitis","enrollment":123},{"nctId":"NCT03404115","phase":"PHASE2","title":"A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2018-01-02","conditions":"Dry Eye Syndrome","enrollment":300},{"nctId":"NCT04097730","phase":"PHASE3","title":"Steroids and Cross-linking for Ulcer Treatment","status":"COMPLETED","sponsor":"Thomas M. Lietman","startDate":"2020-09-24","conditions":"Keratitis Bacterial","enrollment":280},{"nctId":"NCT04391894","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-10-06","conditions":"Dry Eye","enrollment":718},{"nctId":"NCT03879863","phase":"PHASE3","title":"The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2019-04-16","conditions":"Dry Eye","enrollment":422},{"nctId":"NCT06543303","phase":"PHASE2","title":"Evaluation of BTV100 in Subjects With Dry Eye Disease","status":"RECRUITING","sponsor":"BioTheraVision, Inc.","startDate":"2024-12-31","conditions":"Dry Eye","enrollment":120},{"nctId":"NCT06249152","phase":"PHASE2","title":"Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients","status":"COMPLETED","sponsor":"Qlaris Bio, Inc.","startDate":"2024-04-21","conditions":"Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma","enrollment":36},{"nctId":"NCT06016972","phase":"PHASE2","title":"Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients","status":"COMPLETED","sponsor":"Qlaris Bio, Inc.","startDate":"2024-03-05","conditions":"Primary Open Angle Glaucoma (POAG), Primary Open Angle Glaucoma of Both Eyes, Primary Open-Angle Glaucoma, Unspecified Eye","enrollment":63},{"nctId":"NCT05424549","phase":"PHASE2","title":"A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2022-03-09","conditions":"Dry Eye Syndromes","enrollment":63},{"nctId":"NCT04324359","phase":"PHASE2","title":"Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2020-03-03","conditions":"Post-surgical Ocular Inflammation, Post-surgical Ocular Pain","enrollment":91},{"nctId":"NCT05403827","phase":"PHASE3","title":"A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2022-07-03","conditions":"Dry Eye Disease","enrollment":644},{"nctId":"NCT05505292","phase":"PHASE4","title":"Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers","status":"COMPLETED","sponsor":"State University of New York College of Optometry","startDate":"2022-09-22","conditions":"Dry Eye","enrollment":32},{"nctId":"NCT05753189","phase":"PHASE3","title":"Phase 3 Safety Study for the Treatment of Presbyopia Subjects","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2023-02-21","conditions":"Presbyopia, Near Vision, Miosis","enrollment":362},{"nctId":"NCT06128369","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery","status":"TERMINATED","sponsor":"Oculis","startDate":"2023-12-18","conditions":"Inflammation Eye, Pain, Postoperative, Cataract","enrollment":117},{"nctId":"NCT05370495","phase":"PHASE1, PHASE2","title":"Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Seinda Pharmaceutical Guangzhou Corporation","startDate":"2022-07-25","conditions":"Dry Eye Disease","enrollment":201},{"nctId":"NCT04207736","phase":"PHASE3","title":"The INVIGORATE Trial: A Clinical Trial to Assess the Efficacy and Safety of Subjects With Seasonal Allergic Conjunctivitis.","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2019-12-05","conditions":"Allergic Conjunctivitis","enrollment":95},{"nctId":"NCT06360133","phase":"PHASE3","title":"Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease","status":"RECRUITING","sponsor":"VivaVision Biotech, Inc","startDate":"2024-04-01","conditions":"Dry Eye","enrollment":700},{"nctId":"NCT06686472","phase":"PHASE2","title":"Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis","status":"RECRUITING","sponsor":"Telios Pharma, Inc.","startDate":"2024-10-03","conditions":"Allergic Conjunctivitis","enrollment":66},{"nctId":"NCT04250207","phase":"PHASE2","title":"Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2020-06-23","conditions":"Fuchs' Endothelial Corneal Dystrophy","enrollment":65},{"nctId":"NCT05201170","phase":"PHASE3","title":"A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye","status":"COMPLETED","sponsor":"Palatin Technologies, Inc","startDate":"2021-12-30","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":575},{"nctId":"NCT04837482","phase":"PHASE3","title":"A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age","status":"COMPLETED","sponsor":"AbbVie","startDate":"2021-05-14","conditions":"Presbyopia","enrollment":43},{"nctId":"NCT04829344","phase":"PHASE3","title":"A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution","status":"COMPLETED","sponsor":"American Genomics, LLC","startDate":"2021-03-30","conditions":"Anesthesia, Local","enrollment":120},{"nctId":"NCT04909450","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects","status":"COMPLETED","sponsor":"Claris Biotherapeutics, Inc.","startDate":"2021-08-24","conditions":"Neurotrophic Keratitis","enrollment":131},{"nctId":"NCT05431543","phase":"PHASE2","title":"Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2022-08-06","conditions":"Presbyopia, Refractive Errors, Eye Diseases","enrollment":59},{"nctId":"NCT05294328","phase":"PHASE2","title":"Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia","status":"COMPLETED","sponsor":"LENZ Therapeutics, Inc","startDate":"2022-05-05","conditions":"Presbyopia, Refractive Errors, Eye Diseases","enrollment":68},{"nctId":"NCT04498182","phase":"PHASE2","title":"A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye Disease","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2020-10-26","conditions":"Dry Eye Disease","enrollment":369},{"nctId":"NCT05409235","phase":"PHASE2","title":"Nesvategrast (OTT166) in Diabetic Retinopathy (DR)","status":"COMPLETED","sponsor":"OcuTerra Therapeutics, Inc.","startDate":"2022-07-29","conditions":"Diabetic Retinopathy","enrollment":225}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Control"],"phase":"phase_3","status":"active","brandName":"Vehicle Ophthalmic Solution","genericName":"Vehicle Ophthalmic Solution","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vehicle ophthalmic solution is a clear liquid used to lubricate the eyes. Used for Relief of dryness and irritation in the eyes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":9,"withResults":9},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}